ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast…
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
December 03, 2024 16:05 ET | Source: Bionomics Ltd ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) --…
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and the Federation of Asian Biotech Associations (FABA) are…
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and the Federation of Asian Biotech Associations (FABA) are…
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and the Federation of Asian Biotech Associations (FABA) are…
HYDERABAD, India, Nov. 29, 2024 /PRNewswire/ -- Bharath Advanced Therapeutics (BAT) and the Federation of Asian Biotech Associations (FABA) are…